Fig. 2

Human T-cell chimerism in lymph organs and tumors of TNBC mice model a, Growth of MDA-MB-231 tumors in hu-CB-BRGS mice treated (blue line) or untreated (black line) with nivolumab is shown. b, Representative flow plots illustrate gating strategy used to determine human T- and B-cell chimerism. Mouse (mCD45) and human (hCD45) Abs were used to detect species-specific hematopoietic cells (top panels) and hCD3 and hCD20 Abs identified T and B cells, respectively, among the hCD45+ gated cells (bottom panels). A mixture of CB (hPBMC) and mouse spleen cells served as positive staining controls and representative flow plots are from TILs of control or anti-PD-1 treated hu-CB-BRGS mice. 10 tumors were analyzed on d11 and d21 in the control group; 4 tumors on d11 and 6 tumors on d21 were analyzed in the anti-PD-1-treated group. Human immune cell (c), T-cell (d) and CD4 T-cell (e) chimerism in lymph organs and tumors of hu-CB-BRGS mice. CD4+ T-cells are gated on hCD45 + hCD3+. CD8 T-cells are calculated as CD4-negative T-cells. Left panels show percentages in lymph organs, middle panels show frequencies and right panels show relative cell numbers in TILs. Each point represents data from the indicated organ from an individual hu-CB-BRGS mouse that was either untreated (−, black) or treated with nivolumab (+, blue) for 11 or 21 days. P-values: * < 0.05, **** < 0.0001